WEBULL
WebtradeDownload

Will Phase 2 Trial Success Change Cosmo Stock Narrative

Simply Wall St · 2d ago
  • Cosmo Pharmaceuticals reported that its Phase 2 trial of Rifamycin 1% topically acting gel in distal ulcerative colitis and ulcerative proctitis met the primary endpoint, with the company announcing these positive data on 19 October 2026.
  • The Phase 2 success for Rifamycin 1% gel gives Cosmo another potential use case for its gastrointestinal-focused drug delivery expertise. This outcome could broaden future treatment options within its core gastroenterology franchise if later stage studies support these findings.
  • We will now assess how Cosmo's Rifamycin 1% Phase 2 success could reshape the existing investment narrative built around its GI pipeline.

Scan the GI space beyond Cosmo by lining up its news against a curated 129 healthcare AI stocks that are also working on data driven breakthroughs in treatment and care.

Cosmo Investment Narrative Recap

To own Cosmo, you need to believe the gastrointestinal focus, coupled with AI-driven tools and specialty dermatology, can turn a currently loss-making but growing operation into a consistently profitable platform. The recent Phase 2 Rifamycin gel readout adds another GI asset but does not change the near term reality that the group still reported a loss of €6.4 million and remains dependent on execution across a concentrated pipeline.

The most important short term swing factor remains how effectively Cosmo converts its existing products and partnerships into steadier cash generation while funding heavy R&D. Key risks stay intact. Pricing pressure on older ulcerative colitis drugs, exposure to partners such as Medtronic and distributors, and a dividend that is not covered by earnings continue to pull against the growth story.

The fresh Rifamycin data plugs directly into one of Cosmo's main operational themes. Management is trying to leverage proprietary gastrointestinal drug delivery know how across multiple indications, including distal ulcerative colitis and bile acid diarrhoea. Positive Phase 2 results in distal ulcerative colitis and ulcerative proctitis support that goal by keeping this GI program moving through the clinic, in parallel with ongoing work on BAD Treatment and oncology candidate CB 03 10.

Rifamycin's progress also sits alongside AI products like GI Genius and dermatology assets such as Winlevi and the androgen receptor inhibitor for hair loss. Analysts already flag these as major drivers in their models. As you think about catalysts, the Rifamycin trial win adds optionality inside the GI franchise. The biggest operational questions still revolve around regulatory outcomes, partner execution and whether earnings can move from loss to sustainable profit without stretching the balance sheet.

Cosmo's current analyst story points to €215.5 million in revenue and €56.0 million in earnings by 2029. That profile reflects an assumed 27.4% yearly revenue growth rate and an earnings swing of about €59.6 million from a €3.6 million loss today to the projected profit.

Learn why Cosmo's fair value indicates a 133% potential upside to its current price that could materialize more quickly than many investors anticipate.

SWX:CMHC 1-Year Stock Price Chart
SWX:CMHC 1-Year Stock Price Chart

Exploring Other Perspectives

For Cosmo Pharmaceuticals, the bullish twist in the story hinges on recurring income. The most optimistic analysts were already pencilling in revenue of €401.9 million and earnings of €208.2 million by 2029, far above the consensus €215.5 million and €56.0 million. Your takeaway is simple: opinions differ widely and this Rifamycin update could push those narratives to shift again, so treat it as a cue to compare several viewpoints before deciding what feels realistic to you.

Explore 3 other Cosmo fair value estimates, including one that suggests as much as 1836% upside from the current price!

Form Your Own Verdict

Don't just follow the ticker, dig into the data and build a conviction that's truly your own.

Looking for more Cosmo investment ideas?

If Cosmo has sharpened your interest in healthcare opportunities, broaden your watchlist by using the Simply Wall St Screener to hunt for other stocks that match your preferred mix of quality, risk and income potential.